EditorialEditorial
Belimumab in Systemic Lupus Erythematosus — What Can Be Learned from Longterm Observational Studies?
ANDERS A. BENGTSSON
The Journal of Rheumatology February 2014, 41 (2) 192-193; DOI: https://doi.org/10.3899/jrheum.131378
ANDERS A. BENGTSSON
Department of Clinical Sciences, Rheumatology, University Hospital Lund, Lund 22185,
Sweden.
MD, PhDREFERENCES
- 1.↵
- 2.↵
- Becker-Merok A,
- Nossent HC
- 3.↵
- McCarthy EM,
- Lee RZ,
- Ni Gabhann J,
- Smith S,
- Cunnane G,
- Doran MF,
- et al.
- 4.↵
- Ginzler EM,
- Wallace DJ,
- Merrill JT,
- Furie RA,
- Stohl W,
- Chatham WW,
- et al.
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- Merrill JT,
- Neuwelt CM,
- Wallace DJ,
- Shanahan JC,
- Latinis KM,
- Oates JC,
- et al.
- 9.↵
- Ng KP,
- Cambridge G,
- Leandro MJ,
- Edwards JC,
- Ehrenstein M,
- Isenberg DA
- 10.↵
- Merrill JT,
- Burgos-Vargas R,
- Westhovens R,
- Chalmers A,
- D’Cruz D,
- Wallace DJ,
- et al.
- 11.↵
- 12.↵
- 13.↵
- 14.↵
- Ruiz-Irastorza G,
- Ramos-Casals M,
- Brito-Zeron P,
- Khamashta MA
- 15.↵
In this issue
The Journal of Rheumatology
Vol. 41, Issue 2
1 Feb 2014
Belimumab in Systemic Lupus Erythematosus — What Can Be Learned from Longterm Observational Studies?
ANDERS A. BENGTSSON
The Journal of Rheumatology Feb 2014, 41 (2) 192-193; DOI: 10.3899/jrheum.131378